Related Experiment Video

Updated: Apr 28, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.0K

Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic

Maria Rosaria Valerio1, Daniela Sambataro2,3, Federica Martorana4,5

  • 1Medical Oncology Unit, Policlinico, University of Palermo, 90100 Palermo, Italy.

Current Oncology (Toronto, Ont.)
|April 27, 2026
PubMed

Insights

Capivasertib offers a new treatment option for advanced hormone receptor-positive, HER2-negative breast cancer by targeting the PIK3CA/AKT1/PTEN pathway to overcome resistance to endocrine therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Advanced/metastatic hormone receptor-positive, HER2-negative breast cancer (HR+/HER2- BC) often develops resistance to standard first-line therapy (CDK4/6 inhibitors + endocrine therapy).
  • The PIK3CA/AKT1/PTEN pathway is frequently implicated in resistance mechanisms in HR+/HER2- BC.

Purpose of the Study:

  • To review the evidence for capivasertib in advanced HR+/HER2- BC.
  • To focus on preclinical rationale, pharmacology, and clinical challenges of capivasertib.

Main Methods:

  • Narrative review of preclinical and clinical studies.
  • Analysis of studies investigating capivasertib's mechanism of action and efficacy.

Main Results:

  • Capivasertib, a selective AKT kinase inhibitor, is approved in combination with fulvestrant for specific HR+/HER2- BC patients post-endocrine therapy progression.
  • Evidence supports targeting the PIK3CA/AKT1/PTEN pathway to overcome treatment resistance.

Conclusions:

  • Capivasertib represents a significant advancement in managing advanced HR+/HER2- BC with specific molecular alterations.
  • Further understanding of its pharmacology and clinical application is crucial for optimizing patient outcomes.
Keywords:
AKTPI3KPTENcapivasertibfulvestranthormone positive breast cancermTOR

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K